CymaBay Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:CBAY)

Analyst Price Target for CBAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$11.77

▲ +184.28% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $11.77, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 184.28% upside from the last price of $4.14.

Buy

The current consensus among 12 polled investment analysts is to buy stock in CymaBay Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/26/2019

1 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/24/2020

1 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/23/2020

1 strong buy ratings
9 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/22/2020

1 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/20/2020

1 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/18/2021

1 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/19/2021

1 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/31/2021	Cantor Fitzgerald	Lower Price Target	Hold ➝ Overweight	$20.00 ➝ $7.00	Medium	i Rating by A. Young at Cantor Fitzgerald
3/9/2021	Piper Sandler	Reiterated Rating	Buy	$12.00	Low	i Rating by Yasmeen Rahimi at Piper Sandler
11/30/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$9.00 ➝ $10.00	High	i
11/30/2020	Smith Barney Citigroup	Boost Price Target		$9.00 ➝ $10.00	Low	i
11/6/2020	Raymond James	Boost Price Target	Strong-Buy	$11.00 ➝ $12.00	High	i
11/6/2020	SVB Leerink	Boost Price Target	Outperform	$8.00 ➝ $10.00	High	i Rating by T. Smith at SVB Leerink LLC
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium	i Rating by A. Young at Cantor Fitzgerald
9/29/2020	Lifesci Capital	Reiterated Rating	Outperform		Medium	i Rating by P. Dolezal at Lifesci Capital
9/10/2020	Oppenheimer	Reiterated Rating	Buy	$14.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
9/9/2020	B. Riley	Boost Price Target		$9.00 ➝ $13.00	High	i Rating by Mayank Mamtani at B. Riley
8/25/2020	Citigroup	Boost Price Target	Buy	$7.00 ➝ $9.00	Medium	i
8/12/2020	B. Riley	Reiterated Rating	Buy	$9.00	Low	i Rating by Mayank Mamtani at B. Riley
8/11/2020	Raymond James	Boost Price Target	Strong-Buy	$10.00 ➝ $11.00	High	i
8/4/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$15.00 ➝ $20.00	High	i Rating by E. Merle at Cantor Fitzgerald
8/4/2020	HC Wainwright	Boost Price Target	Buy	$9.00 ➝ $13.00	High	i Rating by E. Arce at HC Wainwright
8/4/2020	B. Riley	Reiterated Rating	Buy	$9.00	High	i Rating by Mayank Mamtani at B. Riley
8/3/2020	Oppenheimer	Initiated Coverage	Buy	$12.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/3/2020	Stifel Nicolaus	Boost Price Target	Hold ➝ Buy	$8.00 ➝ $13.00	High	i
7/30/2020	Piper Sandler	Initiated Coverage	Overweight	$12.00	High	i
7/23/2020	Oppenheimer	Boost Price Target	Hold ➝ Outperform	$6.00 ➝ $10.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/23/2020	Raymond James	Upgrade	Outperform ➝ Strong-Buy		High	i
6/22/2020	B. Riley	Reiterated Rating	Buy	$6.00	High	i Rating by Mayank Mamtani at B. Riley
5/26/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$9.00	Medium	i Rating by E. Arce at HC Wainwright
5/15/2020	Citigroup	Boost Price Target	Buy	$1.60 ➝ $7.00	Low	i
5/12/2020	B. Riley	Upgrade	Neutral ➝ Buy	$1.50 ➝ $6.00	Medium	i Rating by Mayank Mamtani at B. Riley
5/12/2020	Roth Capital	Upgrade	Neutral ➝ Buy	$15.00	High	i Rating by Y. Rahimi at Roth Capital
5/12/2020	Cantor Fitzgerald	Boost Price Target	Hold ➝ Overweight	$5.00 ➝ $15.00	High	i Rating by E. Merle at Cantor Fitzgerald
5/12/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$2.50 ➝ $6.00	High	i Rating by Pasha Sarraf at SVB Leerink LLC
5/12/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$4.00 ➝ $8.00	High	i Rating by Derek Archila at Stifel Nicolaus
5/12/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$7.00	High	i Rating by Steven Seedhouse at Raymond James
5/12/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$15.00	High	i Rating by Joshua Schimmer at Evercore ISI
3/20/2020	Citigroup	Lower Price Target	Buy	$2.00 ➝ $1.60	Low	i
3/18/2020	B. Riley	Lower Price Target	Neutral	$2.00 ➝ $1.50	High	i Rating by Mayank Mamtani at B. Riley
3/13/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$2.00 ➝ $5.00	High	i Rating by E. Merle at Cantor Fitzgerald
3/12/2020	Oppenheimer	Upgrade	Market Perform ➝ Buy	$4.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/30/2020	HC Wainwright	Reiterated Rating	Hold		High	i Rating by E. Arce at HC Wainwright
1/2/2020	SVB Leerink	Reiterated Rating	Market Perform		Medium	i Rating by T. Smith at SVB Leerink LLC
12/20/2019	HC Wainwright	Reiterated Rating	Neutral		Low	i Rating by E. Arce at HC Wainwright
11/27/2019	B. Riley	Reiterated Rating	Hold	$2.00	Low	i Rating by Mayank Mamtani at B. Riley
11/26/2019	Roth Capital	Downgrade	Buy ➝ Neutral	$22.00 ➝ $2.00	High	i Rating by Y. Rahimi at Roth Capital
11/26/2019	HC Wainwright	Downgrade	Buy ➝ Neutral	$16.00 ➝ $2.00	High	i Rating by E. Arce at HC Wainwright
11/26/2019	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$20.00 ➝ $2.00	High	i Rating by Eliana Merle at Cantor Fitzgerald
11/26/2019	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High	i Rating by Steven Seedhouse at Raymond James
11/25/2019	Oppenheimer	Downgrade	Outperform ➝ Hold		N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/25/2019	SunTrust Banks	Downgrade	Buy ➝ Hold		N/A	i
11/25/2019	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$4.00	N/A	i
11/24/2019	Evercore ISI	Reiterated Rating	Buy	$12.00	High	i
11/6/2019	HC Wainwright	Reiterated Rating	Buy		Medium	i Rating by E. Arce at HC Wainwright
9/18/2019	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Low	i Rating by Eliana Merle at Cantor Fitzgerald
8/14/2019	Evercore ISI	Reiterated Rating	Buy	$15.00	Low	i
6/24/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$14.00	Low	i
6/17/2019	B. Riley	Set Price Target	Hold	$7.00	Low	i Rating by Mayank Mamtani at B. Riley
6/13/2019	Citigroup	Lower Price Target	Buy	$21.00 ➝ $12.00	High	i Rating by Joel Beatty at Citigroup Inc.
6/12/2019	HC Wainwright	Reiterated Rating	Buy	$24.00 ➝ $12.00	Low	i
6/11/2019	B. Riley	Set Price Target	Hold	$11.00	High	i Rating by Mayank Mamtani at B. Riley
6/11/2019	Oppenheimer	Set Price Target	Buy	$12.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
6/11/2019	Piper Jaffray Companies	Lower Price Target	Overweight ➝ Buy	$30.00 ➝ $8.00	High	i Rating by Tyler Van Buren at Piper Jaffray Companies
5/14/2019	Citigroup	Initiated Coverage	Buy ➝ Buy	$21.00 ➝ $21.00	High	i
4/23/2019	Raymond James	Set Price Target	Buy	$18.00	Low	i Rating by Steven Seedhouse at Raymond James
4/14/2019	Oppenheimer	Set Price Target	Buy	$18.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/14/2019	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Medium	i Rating by Eliana Merle at Cantor Fitzgerald
3/1/2019	Piper Jaffray Companies	Set Price Target	Buy	$30.00	High	i Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019	Cantor Fitzgerald	Set Price Target	Buy	$20.00	High	i Rating by Eliana Merle at Cantor Fitzgerald
2/22/2019	SVB Leerink	Initiated Coverage	Outperform	$22.00	High	i
2/21/2019	SVB Leerink	Reiterated Rating	Outperform		Medium	i Rating by J. Schwartz at SVB Leerink LLC
2/20/2019	Piper Jaffray Companies	Set Price Target	Buy	$30.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
2/19/2019	Roth Capital	Reiterated Rating	Buy		Low	i Rating by Y. Rahimi at Roth Capital
2/15/2019	Oppenheimer	Set Price Target	Buy	$18.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/5/2019	B. Riley	Initiated Coverage	Hold	$9.00 ➝ $9.00	Medium	i Rating by Mayank Mamtani at B. Riley
2/1/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$20.00	High	i Rating by E. Merle at Cantor Fitzgerald
12/9/2018	Oppenheimer	Set Price Target	Buy	$18.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by E. Merle at Cantor Fitzgerald
11/19/2018	HC Wainwright	Reiterated Rating	Buy		High	i
11/13/2018	Oppenheimer	Set Price Target	Buy	$18.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/7/2018	Oppenheimer	Set Price Target	Buy	$18.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/7/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High	i Rating by William Tanner at Cantor Fitzgerald
10/5/2018	Oppenheimer	Set Price Target	Buy	$20.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/10/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$30.00	Low	i
8/9/2018	Oppenheimer	Set Price Target	Buy	$20.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	High	i
6/28/2018	Raymond James	Initiated Coverage	Outperform	$20.00	Medium	i
6/6/2018	HC Wainwright	Reiterated Rating	Buy	$21.00 ➝ $23.00	Medium	i
5/9/2018	Oppenheimer	Set Price Target	Buy	$20.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/17/2018	Oppenheimer	Set Price Target	Buy	$20.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/13/2018	HC Wainwright	Boost Price Target	Buy	$21.00	Low	i
4/11/2018	Oppenheimer	Set Price Target	Buy	$18.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/11/2018	SVB Leerink	Boost Price Target	Outperform	$16.00 ➝ $20.00	High	i
3/28/2018	HC Wainwright	Initiated Coverage	Buy	$18.00	Medium	i
3/21/2018	Oppenheimer	Reiterated Rating	Buy		Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
3/16/2018	SunTrust Banks	Reiterated Rating	Buy	$19.00	High	i
3/16/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$16.00	High	i
3/16/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	Low	i Rating by W. Tanner at Cantor Fitzgerald
3/12/2018	Oppenheimer	Set Price Target	Buy	$18.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/13/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform		High	i
1/25/2018	Roth Capital	Reiterated Rating	Buy ➝ Buy	$27.00	High	i Rating by Y. Rahimi at Roth Capital
1/24/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $18.00	High	i
1/10/2018	Oppenheimer	Set Price Target	Buy	$15.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/28/2017	SVB Leerink	Reiterated Rating	Buy	$16.00	High	i Rating by J. Schwartz at SVB Leerink LLC
11/28/2017	HC Wainwright	Reiterated Rating	Buy	$12.00	Low	i
11/8/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	N/A	i Rating by W. Tanner at Cantor Fitzgerald
10/30/2017	Oppenheimer	Set Price Target	Buy	$15.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$12.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	High	i Rating by W. Tanner at Cantor Fitzgerald
9/19/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$16.00	High	i Rating by W. Tanner at Cantor Fitzgerald
8/23/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$12.00	Low	i Rating by J. Schwartz at SVB Leerink LLC
8/18/2017	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$15.00	High	i
8/11/2017	Ifs Securities	Downgrade	Strong-Buy ➝ Outperform		High	i Rating by D. Bouchey at Ifs Securities
7/25/2017	Piper Jaffray Companies	Reiterated Rating	Positive ➝ Overweight	$12.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
7/20/2017	CIBC	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $15.00	Medium	i
7/20/2017	Oppenheimer	Boost Price Target	Outperform	$8.00 ➝ $15.00	Medium	i
7/20/2017	Citigroup	Reiterated Rating	Outperform	$8.00 ➝ $15.00	Medium	i
7/17/2017	Ifs Securities	Reiterated Rating	Strong-Buy		Low	i Rating by D. Bouchey at Ifs Securities
7/17/2017	Piper Jaffray Companies	Set Price Target	Buy	$7.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
7/17/2017	HC Wainwright	Boost Price Target	Buy	$7.00 ➝ $12.00	High	i Rating by E. Arce at HC Wainwright
6/23/2017	Oppenheimer	Initiated Coverage	Outperform	$8.00	High	i
3/27/2017	HC Wainwright	Reiterated Rating	Buy	$6.00 ➝ $7.00	High	i Rating by E. Arce at HC Wainwright
3/24/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$5.00 ➝ $6.50	High	i
1/30/2017	HC Wainwright	Upgrade	Neutral ➝ Buy	$2.50 ➝ $6.00	N/A	i Rating by E. Arce at HC Wainwright
1/4/2017	HC Wainwright	Boost Price Target	Neutral	$1.50 ➝ $2.50	N/A	i
7/1/2016	Roth Capital	Initiated Coverage	Buy		N/A	i Rating by S. Yaniv at Roth Capital
6/1/2016	HC Wainwright	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.25	N/A	i Rating by Ed Arce at HC Wainwright
5/12/2016	HC Wainwright	Reiterated Rating	Buy		N/A	i Rating by Ed Arce at HC Wainwright

(Data available from 4/19/2016 forward)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Today's Range

Now: $4.14

$4.14

$4.41

50 Day Range

MA: $4.68

$4.19

$5.18

52 Week Range

Now: $4.14

$1.50

$9.06

Volume

36,512 shs

Average Volume

1,132,079 shs

Market Capitalization

$285.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, HC Wainwright, Lifesci Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CBAY.

What is the current price target for CymaBay Therapeutics?

13 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $11.77, suggesting a possible upside of 184.3%. Roth Capital has the highest price target set, predicting CBAY will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.

What is the current consensus analyst rating for CymaBay Therapeutics?

CymaBay Therapeutics currently has 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics.
View the latest ratings for CBAY.

What other companies compete with CymaBay Therapeutics?

Other companies that are similar to CymaBay Therapeutics include Protagonist Therapeutics, Avid Bioservices, Phathom Pharmaceuticals, Mersana Therapeutics, Nkarta, Y-mAbs Therapeutics, Omeros, Stoke Therapeutics, Northwest Biotherapeutics, Pliant Therapeutics, Constellation Pharmaceuticals, Kiniksa Pharmaceuticals, Arcturus Therapeutics, Zogenix and Praxis Precision Medicines.

How do I contact CymaBay Therapeutics' investor relations team?

CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is 510-293-8800 and its investor relations email address is [email protected] The official website for CymaBay Therapeutics is www.cymabay.com.

NASDAQ:CBAY - CymaBay Therapeutics Stock Price Target and Predictions

Analyst Price Target for CBAY

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

What is the current price target for CymaBay Therapeutics?

What is the current consensus analyst rating for CymaBay Therapeutics?

What other companies compete with CymaBay Therapeutics?

How do I contact CymaBay Therapeutics' investor relations team?